Status:
UNKNOWN
Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.
Lead Sponsor:
PETHEMA Foundation
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
Eligibility:
All Genders
Brief Summary
The proposal of this study is to retrospectively analyze the experience with belantamab mafodotin monotherapy in patients with RRMM included in the compassionate use or in the expanded access program ...
Detailed Description
The proposal of this study is to retrospectively analyze the experience with belantamab mafodotin monotherapy in patients with RRMM included in the compassionate use or in the expanded access program ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Reception of at least one dose of belantamab mafodotin as part of the compassionate use or the expanded access program in Spain between November 2019 and June 2021
Exclusion
Key Trial Info
Start Date :
March 24 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT05297240
Start Date
March 24 2022
End Date
December 1 2022
Last Update
August 5 2022
Active Locations (62)
Enter a location and click search to find clinical trials sorted by distance.
1
H. Universitario de Albacete
Albacete, Spain
2
H. Doctor José Molina Orosa
Arrecife, Spain
3
H. San Agustín
Avilés, Spain
4
H. Ntra. Señora Sonsoles
Ávila, Spain